PURPOSE: Coronary vasomotor dysfunction embraces two specific clinical entities: coronary (micro)vascular spasm and microvascular dysfunction. The clinical manifestations of these entities are respectively called vasospastic angina (VSA) and microvascular angina (MVA). Over the years, these diseases have become more and more prominent and several studies aimed to investigate the best diagnostic and therapeutic strategies. Patients with coronary vasomotor disorders are often undertreated due to the absence of evidence-based guidelines. The purpose of this overview is to illustrate the various therapeutic options available for the optimized management of these patients. METHODS: A Medline search of full-text articles published in English from 1980 to April 2022 was performed. The main analyzed aspects of vasomotor disorders were treatment options. We also performed research on "Clinicaltrial.gov" for ongoing trials. CONCLUSION: Coronary (micro)vascular spasm and microvascular dysfunction are clinical entities characterized by high prevalence and clinical representation. Several therapeutic strategies, both innovative and established, are available to optimize treatment and improve the quality of life of these patients.
PURPOSE: Coronary vasomotor dysfunction embraces two specific clinical entities: coronary (micro)vascular spasm and microvascular dysfunction. The clinical manifestations of these entities are respectively called vasospastic angina (VSA) and microvascular angina (MVA). Over the years, these diseases have become more and more prominent and several studies aimed to investigate the best diagnostic and therapeutic strategies. Patients with coronary vasomotor disorders are often undertreated due to the absence of evidence-based guidelines. The purpose of this overview is to illustrate the various therapeutic options available for the optimized management of these patients. METHODS: A Medline search of full-text articles published in English from 1980 to April 2022 was performed. The main analyzed aspects of vasomotor disorders were treatment options. We also performed research on "Clinicaltrial.gov" for ongoing trials. CONCLUSION: Coronary (micro)vascular spasm and microvascular dysfunction are clinical entities characterized by high prevalence and clinical representation. Several therapeutic strategies, both innovative and established, are available to optimize treatment and improve the quality of life of these patients.
Authors: Lasse Jespersen; Anders Hvelplund; Steen Z Abildstrøm; Frants Pedersen; Søren Galatius; Jan K Madsen; Erik Jørgensen; Henning Kelbæk; Eva Prescott Journal: Eur Heart J Date: 2011-09-11 Impact factor: 29.983
Authors: Manesh R Patel; Eric D Peterson; David Dai; J Matthew Brennan; Rita F Redberg; H Vernon Anderson; Ralph G Brindis; Pamela S Douglas Journal: N Engl J Med Date: 2010-03-11 Impact factor: 91.245
Authors: Barry Sharaf; Todd Wood; Leslee Shaw; B Delia Johnson; Sheryl Kelsey; R David Anderson; Carl J Pepine; C Noel Bairey Merz Journal: Am Heart J Date: 2013-05-02 Impact factor: 4.749
Authors: John F Beltrame; Filippo Crea; Juan Carlos Kaski; Hisao Ogawa; Peter Ong; Udo Sechtem; Hiroaki Shimokawa; C Noel Bairey Merz Journal: Eur Heart J Date: 2017-09-01 Impact factor: 29.983
Authors: Haseeb Rahman; David Corcoran; Muhammad Aetesam-Ur-Rahman; Stephen P Hoole; Colin Berry; Divaka Perera Journal: Heart Date: 2019-07-31 Impact factor: 5.994
Authors: Vijay Kunadian; Alaide Chieffo; Paolo G Camici; Colin Berry; Javier Escaned; Angela H E M Maas; Eva Prescott; Nicole Karam; Yolande Appelman; Chiara Fraccaro; Gill Louise Buchanan; Stéphane Manzo-Silberman; Rasha Al-Lamee; Evelyn Regar; Alexandra Lansky; J Dawn Abbott; Lina Badimon; Dirk J Duncker; Roxana Mehran; Davide Capodanno; Andreas Baumbach Journal: EuroIntervention Date: 2021-01-20 Impact factor: 6.534
Authors: Thomas J Ford; Peter Ong; Udo Sechtem; John Beltrame; Paolo G Camici; Filippo Crea; Juan-Carlos Kaski; C Noel Bairey Merz; Carl J Pepine; Hiroaki Shimokawa; Colin Berry Journal: JACC Cardiovasc Interv Date: 2020-08-24 Impact factor: 11.075